Rooted in Our History, Looking Toward Tomorrow 

 

 

For over a century, Guerbet has been the essential partner in medical imaging. This wealth of experience is our strength: it guides us, inspires us, and drives us to push boundaries for the next century.
Our promise? Proven efficiency, shared trust, and a pioneering spirit that allows us to see things differently—with ever greater precision, clarity, and contrast.

 

Innovation at the heart of our DNA

For 100 years, we have explored the full potential of medical imaging in collaboration with the scientific community to develop innovative solutions.
From Lipiodol®, created in 1901 and still used for new indications, to our benchmark contrast agents for MRI (Dotarem®, Elucirem®) and X-ray imaging (Xenetix®, Hexabrix®, Telebrix®), Guerbet has made its mark on the history of radiology.
Today, our augmented intelligence solutions support healthcare professionals in achieving earlier and more accurate diagnoses, helping to save lives. This constant capacity for innovation, backed by the Guerbet family, ensures sustainable growth.

 

Reference Solutions That Make a Difference 

At every moment, our products contribute to more accurate diagnoses for millions of patients.
Our commitment to maintaining the quality and reliability of our products has earned the trust of thousands of healthcare professionals worldwide.

Proximity as a Legacy

As an independent, family-owned, human-scale company, we cultivate a privileged relationship with our partners.
Present on five continents, we remain attentive to their needs and respond with relevance and agility.
Our roots are French, but our branches continue to spread internationally so that medical progress is accessible to all.
We are 100 years old, and more than ever, our pioneering spirit allows us to see things differently—with ever greater precision, clarity, and contrast—serving a medicine that is increasingly accessible, personalized, and human.

 


GUERBET: VISIBLY DIFFERENT FOR 100 YEARS.

 

Key Dates in Guerbet's History

This timeline illustrates the growth of the Guerbet Group and its major innovations:

  • 1901: Invention of Lipiodol®
    Marcel Guerbet develops an iodized oil, Lipiodol®. Its opacifying properties, discovered in 1918, make it the first iodinated contrast agent.
  • 1926: Birth of the Laboratory
    Marcel Guerbet and his son André set up a chemical and pharmaceutical production site in Saint-Ouen. New contrast products are used in uro-angiography, bronchography, and hysterosalpingography.
  • 1972: International Expansion
    Guerbet opens its first international subsidiary in Brazil in 1972.
  • 1980: Lipiodol® in Interventional Radiology
    The first chemoembolization procedures are performed in Japan using Lipiodol® Ultra-Fluide to treat patients with hepatocellular carcinoma.
  • 1987: Acquisition of Simafex (fine chemistry)
  • 1989: Launch of Dotarem® for MRI in France
  • 1993: MRI range expands with new products: Lumirem® (1993), Xenetix® (1994, X-rays), and Endorem® (1995).
  • 2015: Acquisition of Mallinckrodt’s “Contrast Media and Delivery Systems” business
    Guerbet acquires Mallinckrodt’s CMDS activity, creating a new global leader in imaging solutions and services.
  • 2022: Launch of Elucirem™ in the US; direct operations in India and China
  • 2023: Intrasense joins Guerbet Group
  • 2023: Marketing authorization for Elucirem™ (Gadopiclenol) in the European Union
  • 2024: Strategic partnership between Guerbet and Nuclidium in radiotheranostics